The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.

The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) initiative has already defined clinical signs, symptoms, quality of life, and long-term control of flares as core outcome domains for AE trials. This article deals with the standardization of measurement instruments to assess clinical signs of AE. To resolve the current lack of standardization of the assessment of clinical signs of AE, we followed a structured process of systematic reviews and international consensus sessions to identify 1 core outcome measurement instrument for assessment of clinical signs in all future AE trials. Systematic reviews indicated that from 16 different instruments identified to assess clinical signs of AE, only the Eczema Area and Severity Index (EASI) and the objective Scoring Atopic Dermatitis (SCORAD) index were identified as extensively validated. The EASI has adequate validity, responsiveness, internal consistency, and intraobserver reliability. The objective SCORAD index has adequate validity, responsiveness, and interobserver reliability but unclear intraobserver reliability to measure clinical signs of AE. In an international consensus study, patients, physicians, nurses, methodologists, and pharmaceutical industry representatives agreed that the EASI is the preferred core instrument to measure clinical signs in all future AE trials. All stakeholders involved in designing, reporting, and using clinical trials on AE are asked to comply with this consensus to enable better evidence-based decision making, clearer scientific communication, and improved patient care.

[1]  H. Williams,et al.  Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. , 2011, The Journal of investigative dermatology.

[2]  H. Williams,et al.  Harmonising Outcome Measures for Eczema (HOME).Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany , 2010, The British journal of dermatology.

[3]  H. Yang,et al.  Evaluation of patient's subjective severity using various scoring system in Korean children with atopic dermatitis. , 2010, Asian Pacific journal of allergy and immunology.

[4]  D. Solé,et al.  Severity scoring of atopic dermatitis: a comparison of two scoring systems. , 2008, Allergologia et immunopathologia.

[5]  H. Ko,et al.  Does the EASI score reflect itch severity? , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  J. Schmitt,et al.  EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference , 2012, Allergy.

[7]  N. Fukiwake,et al.  Severity of disease, rather than xerosis, correlates with pruritus in patients with atopic dermatitis , 2009, International journal of dermatology.

[8]  P. Tugwell,et al.  OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. , 1993, The Journal of rheumatology.

[9]  H. Williams,et al.  Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting , 2012, Allergy.

[10]  H. Williams,et al.  The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.

[11]  J. Schmitt,et al.  Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME) , 2014, The British journal of dermatology.

[12]  P G Mulder,et al.  Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. , 1999, Acta dermato-venereologica.

[13]  H. Williams,et al.  What are the best outcome measurements for atopic eczema? A systematic review. , 2007, The Journal of allergy and clinical immunology.

[14]  Rajesh Balkrishnan,et al.  The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society , 2005, Pediatric dermatology.

[15]  J. Ring,et al.  Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. , 1997, Dermatology.

[16]  Hywel C Williams,et al.  Clinical practice. Atopic dermatitis. , 2005, The New England journal of medicine.

[17]  M. Graeber,et al.  Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis , 1998 .

[18]  W. Kuis,et al.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. , 2003, Rheumatology.

[19]  J Berth-Jones,et al.  Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis * , 1996, The British journal of dermatology.

[20]  C. Terwee,et al.  The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. , 2010, Journal of clinical epidemiology.

[21]  P. Tugwell,et al.  The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.

[22]  P. Elsner,et al.  The Objective Severity Assessment of Atopic Dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis , 2005, The British journal of dermatology.

[23]  Jochen Schmitt,et al.  Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. , 2013, The Journal of allergy and clinical immunology.

[24]  H. Williams,et al.  Mapping randomized controlled trials of treatments for eczema - The GREAT database (The Global Resource of Eczema Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010) , 2011, BMC dermatology.

[25]  M. D. de Bruin‐Weller,et al.  Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  P. Tugwell,et al.  OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.

[27]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[28]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[29]  P. Williamson,et al.  Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people , 2012, Trials.

[30]  U. Wahn,et al.  Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. , 2008, Acta dermato-venereologica.

[31]  Jane M Blazeby,et al.  Developing core outcome sets for clinical trials: issues to consider , 2012, Trials.

[32]  T. Luger,et al.  Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme , 2004, The British journal of dermatology.

[33]  P. Tugwell,et al.  Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. , 1997, The Journal of rheumatology.

[34]  J. Schmitt,et al.  Schram ME, Spuls PI, Leeflang MM et al.EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 67:99-106 , 2011 .

[35]  A. Armstrong,et al.  Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010 , 2011, PloS one.

[36]  K. Hon,et al.  Lesson from performing SCORADs in children with atopic dermatitis: Subjective symptoms do not correlate well with disease extent or intensity , 2006, International journal of dermatology.

[37]  E. Novembre,et al.  Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index , 2005, Allergy.

[38]  H. Williams,et al.  Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? , 2003, The Journal of investigative dermatology.

[39]  H. Williams,et al.  Measuring atopic eczema severity visually: which variables are most important to patients? , 2005, Archives of dermatology.